1.63
0.29 (21.64%)
| Previous Close | 1.34 |
| Open | 1.37 |
| Volume | 35,935,499 |
| Avg. Volume (3M) | 12,870,252 |
| Market Cap | 1,045,679,168 |
| Price / Sales | 4.56 |
| Price / Book | 3.75 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -119.54% |
| Operating Margin (TTM) | -42.18% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 12,927.30% |
| Total Debt/Equity (MRQ) | 45.40% |
| Current Ratio (MRQ) | 7.86 |
| Operating Cash Flow (TTM) | -204.34 M |
| Levered Free Cash Flow (TTM) | -142.38 M |
| Return on Assets (TTM) | -16.07% |
| Return on Equity (TTM) | -45.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Geron Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 81.26% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |